ROBOSENSE
8.10.2021 16:02:05 CEST | Business Wire | Press release
RoboSense was named a 2021 Automotive News PACE Award winner at the online awards ceremony on September 30. The prestigious award recognizes automotive suppliers for superior innovation, technological advances and business performance in the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211008005293/en/
RoboSense was recognized for RS-LiDAR-M1 (M1), its MEMS LiDAR and the world’s first mass-produced automotive-grade second-generation solid-state LiDAR . The system generates an accurate, reliable 3D point cloud that improves perception redundancy and safety, and empowers smart vehicles with a safer, more comfortable driver-passenger experience.
Building on its second-generation LiDAR technology, M1 boasts an exclusive intelligent functionality named “GAZE” which dynamically enhances resolution or frame rate based on the environment. RoboSense’s patented MEMS technology, modular design and integrated system architecture deliver high-reliability and high-performance in a compact design. With its reduced number of components, it enables more potential for upgrades at lower costs in the future.
Dr. Leilei Shinohara, Vice President of RoboSense, said, “M1 is tailored for autonomous driving and ADAS systems. Its mass production launch this year is an achievement marked by years of investment and research. Our unique MEMS technology provides a high-performance and low-cost solution with highly-accurate perception to support auto manufacturer’s mass production and the ultimate transformation to autonomous driving.”
The 27th annual PACE Awards were presented by Automotive News and the Automotive Parts Manufacturers’ Association (APMA). The competition was open to suppliers that contribute products, processes, materials or services directly to the manufacturing of cars or trucks. The Automotive News PACE Award is recognized around the world as the industry benchmark for innovation.
RoboSense earned an Automotive News PACE Award following an extensive review by an independent panel of judges, including a comprehensive written application and a virtual site visit.
For complete details of the Automotive News PACE Award, visit www.autonews.com/pace . To learn more about RoboSense, visit www.robosense.ai , and follow the company on LinkedIn and Twitter .
About RoboSense
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world-leading provider of Smart LiDAR Sensor Systems. Comprising LiDAR sensors, AI perception and IC chipsets, its portfolio transforms conventional 3D LiDAR sensors with comprehensive data analysis and interpretation systems. The company's mission is to innovate outstanding hardware and artificial intelligence capabilities to create smart solutions that enable robots, including vehicles, to have perception capabilities superior to humans.
About PACE Award
The Automotive News PACE program honors superior innovation, technological advancement and business performance among automotive suppliers. Judged by an independent panel of technologists, they are recognized around the world as the industry benchmark for innovation. Traditional and non-traditional suppliers, as well as startups, submit applications for whichever program they qualify for, for evaluation by our independent panel of more than 20 judges. Innovations eligible for the PACE Award must be commercialized and sold to an OEM customer.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211008005293/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom